Stratasys develops industrial grade additive solutions to help you solve critical design and manufacturing challenges, right along your production cycle. Working with you to push the boundaries of what’s possible. And thrive in a changing world. Make additive work for you™.
Aspect Biosystems is a biotechnology company pioneering the development of a novel category of cellular medicines designed to replace or restore biological function and deliver curative therapies for some of the most elusive diseases. Aspect is developing these bioengineered cellular medicines by applying its full-stack tissue therapeutic platform, which integrates proprietary AI-powered bioprinting technology, therapeutic cells, hypoimmune cell engineering, and advanced biomaterials. Aspect is advancing its therapeutic pipeline across multiple endocrine and metabolic diseases, including diabetes and rare endocrine disorders.
BICO leverages a global portfolio of pioneering brands fusing automation, intelligence, and data to unlock scientific discovery at scale in pharma and biotech. With 53,600+ instruments installed in over 65 countries, BICO products, software, and solutions are found in more than 3,500 laboratories, including the world’s top 20 pharmaceutical companies, and have been cited in over 13,000 publications. BICO strives towards the vision to enable life-science labs to accelerate the discoveries that change lives. BICO is listed on Mid-Cap, Nasdaq Stockholm under BICO.
BICO exists so therapies reach humanity sooner
Progress has never moved fast enough for those waiting - for a therapy, for a breakthrough, for hope to turn into healing.
BICO reignites the pace and transformation of scientific advancement.
We serve as the catalyst for a truly connected era of life sciences - where technology, data, and human potential move together in seamless flow, turning every result into the next discovery, and every discovery into a new possibility.
Through our global portfolio of pioneering brands, we unite people, ideas and evidence - transforming the way science advances - from fragmented and reactive to continuous and intelligent.
Because true progress demands it - that therapies reach people faster, for the good of humanity.